A new pancreatic cancer treatment, daraxonrasib, is making strides in early trials. This pill targets cancer signals associated with the RAS gene. The first phase of human trials is complete, assessing both its safety and efficacy.
Clinical Trial Insights
Conducted by the Dana-Farber Cancer Institute, the trial included 168 patients with advanced pancreatic cancer, all having previously undergone chemotherapy. The primary goal was to target mutations in the RAS gene, prevalent in over 90% of pancreatic cancers.
Research highlights that previous drugs targeting RAS mutations were less effective for pancreatic cancer. At a 300-milligram dose, a 30% positive response rate was observed. Additionally, 90% of participants saw their cancer shrink or remain stable.
Side Effects and Reactions
Some patients experienced side effects like rash, mouth inflammation, nausea, and diarrhea. Despite this, most tolerated the treatment well without needing to discontinue it.
Future Implications
Lead investigator Dr. Brian Wolpin emphasizes the potential impact of daraxonrasib. The trial indicates disease control in 90% of patients with metastatic pancreatic cancer, a significant achievement given the limited effectiveness of previous therapies.
Wolpin cautions that daraxonrasib’s superiority over chemotherapy is not yet confirmed. Further studies are necessary to compare effectiveness and to explore its application earlier in disease progression. He stresses ongoing research to determine optimal therapy combinations.
Dr. Brian Slomovitz from the Mount Sinai Medical Center praises the promising results. He anticipates the upcoming RASolute 302 presentation at the ASCO meeting, hoping it confirms earlier findings.
Slomovitz notes the potential to double survival time in pretreated patients, which is unprecedented. The outcome may redefine treatment standards and significantly benefit those affected by pancreatic cancer.
Angelica Stabile reports this development for Fox News Digital, highlighting its importance for patients and their families.